CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.28 billion. The enterprise value is $2.12 billion.
| Market Cap | 1.28B |
| Enterprise Value | 2.12B |
Important Dates
The last earnings date was Wednesday, January 28, 2026, after market close.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CONMED has 30.83 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 30.83M |
| Shares Outstanding | 30.83M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.85% |
| Owned by Institutions (%) | 111.96% |
| Float | 30.55M |
Valuation Ratios
The trailing PE ratio is 27.42 and the forward PE ratio is 9.51. CONMED's PEG ratio is 1.82.
| PE Ratio | 27.42 |
| Forward PE | 9.51 |
| PS Ratio | 0.93 |
| Forward PS | 0.91 |
| PB Ratio | 1.24 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.46 |
| P/OCF Ratio | 7.48 |
| PEG Ratio | 1.82 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.53, with an EV/FCF ratio of 14.07.
| EV / Earnings | 45.12 |
| EV / Sales | 1.54 |
| EV / EBITDA | 10.53 |
| EV / EBIT | 16.51 |
| EV / FCF | 14.07 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.86.
| Current Ratio | 2.14 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 4.17 |
| Debt / FCF | 5.88 |
| Interest Coverage | 4.14 |
Financial Efficiency
Return on equity (ROE) is 4.72% and return on invested capital (ROIC) is 4.60%.
| Return on Equity (ROE) | 4.72% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 4.60% |
| Return on Capital Employed (ROCE) | 6.39% |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | $352,493 |
| Profits Per Employee | $12,065 |
| Employee Count | 3,900 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, CONMED has paid $24.06 million in taxes.
| Income Tax | 24.06M |
| Effective Tax Rate | 33.83% |
Stock Price Statistics
The stock price has decreased by -28.25% in the last 52 weeks. The beta is 0.90, so CONMED's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -28.25% |
| 50-Day Moving Average | 42.02 |
| 200-Day Moving Average | 47.64 |
| Relative Strength Index (RSI) | 40.96 |
| Average Volume (20 Days) | 497,519 |
Short Selling Information
The latest short interest is 846,967, so 2.75% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.75% |
| Short % of Float | 2.77% |
| Short Ratio (days to cover) | 3.22 |
Income Statement
In the last 12 months, CONMED had revenue of $1.37 billion and earned $47.06 million in profits. Earnings per share was $1.51.
| Revenue | 1.37B |
| Gross Profit | 740.58M |
| Operating Income | 128.57M |
| Pretax Income | 71.12M |
| Net Income | 47.06M |
| EBITDA | 201.65M |
| EBIT | 128.57M |
| Earnings Per Share (EPS) | $1.51 |
Balance Sheet
The company has $40.82 million in cash and $887.49 million in debt, with a net cash position of -$846.67 million or -$27.46 per share.
| Cash & Cash Equivalents | 40.82M |
| Total Debt | 887.49M |
| Net Cash | -846.67M |
| Net Cash Per Share | -$27.46 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 33.36 |
| Working Capital | 357.82M |
Cash Flow
In the last 12 months, operating cash flow was $170.69 million and capital expenditures -$19.81 million, giving a free cash flow of $150.88 million.
| Operating Cash Flow | 170.69M |
| Capital Expenditures | -19.81M |
| Free Cash Flow | 150.88M |
| FCF Per Share | $4.89 |
Margins
Gross margin is 53.87%, with operating and profit margins of 9.35% and 3.42%.
| Gross Margin | 53.87% |
| Operating Margin | 9.35% |
| Pretax Margin | 5.17% |
| Profit Margin | 3.42% |
| EBITDA Margin | 14.67% |
| EBIT Margin | 9.35% |
| FCF Margin | 10.98% |
Dividends & Yields
This stock pays an annual dividend of $0.60, which amounts to a dividend yield of 1.45%.
| Dividend Per Share | $0.60 |
| Dividend Yield | 1.45% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 39.74% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 1.45% |
| Earnings Yield | 3.69% |
| FCF Yield | 11.82% |
Analyst Forecast
The average price target for CONMED is $51.20, which is 23.67% higher than the current price. The consensus rating is "Hold".
| Price Target | $51.20 |
| Price Target Difference | 23.67% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.08 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 6 |